{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:39:58Z","timestamp":1792517998876,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021078","name":"Norwegian Institute of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021078","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003506","name":"Norwegian Ministry of Health and Care Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003506","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128511","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:51:58Z","timestamp":1774515118000},"page":"128511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-lasting cross-reactive and polyfunctional SARS-CoV-2 T cell responses in seniors are maintained after repeated vaccination and infections"],"prefix":"10.1016","volume":"80","author":[{"given":"Anna Hayman","family":"Robertson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asia-Sophia","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Even","family":"Fossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guri","family":"Solum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabin","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Lea","family":"Vikse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid Fadum","family":"Kj\u00f8nstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Magnus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unni C.","family":"Nygaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fridtjof","family":"Lund-Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lill","family":"Trogstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"Mjaaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128511_bb0005","article-title":"In-hospital mortality during the wild-type, alpha, delta, and omicron SARS-CoV-2 waves: a multinational cohort study in the EuCARE project","volume":"38","author":"Hedberg","year":"2024","journal-title":"Lancet Reg Health \u2013 Eur"},{"key":"10.1016\/j.vaccine.2026.128511_bb0010","author":"WHO"},{"key":"10.1016\/j.vaccine.2026.128511_bb0015","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-023-02220-y","article-title":"When to update COVID-19 vaccine composition","volume":"29","author":"Grant","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128511_bb0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-CoV-2 vaccine\u2013induced immunity: a systematic review and meta-analysis","volume":"6","author":"Menegale","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128511_bb0025","article-title":"SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination","author":"Nguyen","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128511_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2024.01.017","article-title":"SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase","volume":"57","author":"Srivastava","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128511_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127459","article-title":"Exposure to two antigenically distinct SARS-CoV-2 variants broadens neutralization patterns","volume":"62","author":"Schmitt","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128511_bb0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41541-023-00616-y","article-title":"Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern","volume":"8","author":"Azevedo","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128511_bb0045","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41590-024-01787-z","article-title":"Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination","volume":"25","author":"Fumagalli","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2026.128511_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2026.128511_bb0055","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/S2666-7568(23)00055-7","article-title":"Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study","volume":"4","author":"Ravussin","year":"2023","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.vaccine.2026.128511_bb0060","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1038\/s41467-022-32312-1","article-title":"Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose","volume":"13","author":"Renia","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128511_bb0065","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41564-021-01046-z","article-title":"Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults","volume":"7","author":"Romero-Olmedo","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2026.128511_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128511_bb0075","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41467-024-46490-7","article-title":"Distinct evolution of SARS-CoV-2 omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion","volume":"15","author":"Planas","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128511_bb0080","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41590-024-02051-0","article-title":"T cell immune evasion by SARS-CoV-2 JN.1 escapees targeting two cytotoxic T cell epitope hotspots","volume":"26","author":"Tian","year":"2025","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2026.128511_bb0085","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1038\/s41467-022-31888-y","article-title":"Immune responses in omicron SARS-CoV-2 breakthrough infection in vaccinated adults","volume":"13","author":"Kared","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128511_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115314","article-title":"Hybrid immunity-based induction of durable pan-endemic-coronavirus immunity in the elderly","volume":"44","author":"Loyal","year":"2025","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2026.128511_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adh0687","article-title":"SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19","volume":"8","author":"Cai","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2026.128511_bb0100","article-title":"Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later","volume":"90","author":"Rubio","year":"2025","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2026.128511_bb0105","article-title":"Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study","volume":"48","author":"\u00d8rbo","year":"2025","journal-title":"Lancet Reg Health \u2013 Eur"},{"key":"10.1016\/j.vaccine.2026.128511_bb0110","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41541-022-00586-7","article-title":"Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants","volume":"7","author":"Tran","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.128511_bb0115","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/infdis\/jiac263","article-title":"Anti-membrane antibodies persist at least one year and discriminate between past coronavirus disease 2019 infection and vaccination","volume":"226","author":"Amjadi","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128511_bb0120","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13144","article-title":"Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022","volume":"17","author":"Vikse","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2026.128511_bb0125","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nbt.3187","article-title":"COMPASS identifies T-cell subsets correlated with clinical outcomes","volume":"33","author":"Lin","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2026.128511_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105317","article-title":"T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study","volume":"108","author":"Wolf","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2026.128511_bb0135","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1186\/s12879-024-09670-w","article-title":"Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults","volume":"24","author":"Tunheim","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128511_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107056","article-title":"Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy","volume":"26","author":"Williams","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.vaccine.2026.128511_bb0145","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-021-03647-4","article-title":"SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans","volume":"595","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128511_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70102","article-title":"Low levels of neutralizing antibodies against SARS-CoV-2 KP.3.1.1 and XEC in serum from seniors in May 2024","volume":"19","author":"Fossum","year":"2025","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2026.128511_bb0155","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S1473-3099(24)00738-2","article-title":"Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations","volume":"25","author":"Liu","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128511_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105912","article-title":"Impact of systemic SARS-CoV-2 vaccination on mucosal IgA responses to subsequent breakthrough infection","volume":"120","author":"Marking","year":"2025","journal-title":"eBioMedicine"},{"key":"10.1016\/j.vaccine.2026.128511_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1513175","article-title":"The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells","volume":"16","author":"Sop","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128511_bb0170","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.vaccine.2016.02.063","article-title":"Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection","volume":"34","author":"Ng","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128511_bb0175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41467-022-34033-x","article-title":"SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19","volume":"14","author":"Stanevich","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128511_bb0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41541-023-00794-9","article-title":"A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation","volume":"9","author":"Binayke","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.128511_bb0185","article-title":"Allelic variation in class I HLA determines CD8<sup>+<\/sup> T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2","volume":"7","author":"Francis","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2026.128511_bb0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12979-020-00181-1","article-title":"The immune response to influenza in older humans: beyond immune senescence","volume":"17","author":"McElhaney","year":"2020","journal-title":"Immun Ageing"},{"key":"10.1016\/j.vaccine.2026.128511_bb0195","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12979-025-00504-0","article-title":"CD31 + na\u00efve T cells associate with immunosenescence and responsiveness to multiple vaccines in older adults","volume":"22","author":"Cevirgel","year":"2025","journal-title":"Immun Ageing"},{"key":"10.1016\/j.vaccine.2026.128511_bb0200","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41541-024-01028-2","article-title":"Mass cytometry reveals cellular correlates of immune response heterogeneity to SARS-CoV-2 vaccination in the elderly","volume":"9","author":"Mukherjee","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128511_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(17)30155-X","article-title":"Immunisation of older adults: where are the frail?","volume":"2","author":"Chhetri","year":"2017","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.vaccine.2026.128511_bb0210","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s43587-022-00343-4","article-title":"Impaired CD4+ T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination","volume":"3","author":"Jo","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.vaccine.2026.128511_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2024.100564","article-title":"Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults","volume":"20","author":"Bredholt","year":"2024","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2026.128511_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1455334","article-title":"Booster COVID-19 mRNA vaccination ameliorates impaired B-cell but not T-cell responses in older adults","volume":"15","author":"Kometani","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128511_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115907","article-title":"Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters","volume":"44","author":"da Silva Antunes","year":"2025","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2026.128511_bb0230","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01350-24","article-title":"Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination","volume":"99","author":"Karl","year":"2025","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128511_bb0235","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41591-024-02962-3","article-title":"Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children","volume":"30","author":"Zhong","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128511_bb0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1126\/science.adh2712","article-title":"Variant-adapted COVID-19 booster vaccines","volume":"382","author":"Krammer","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128511_bb0245","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1038\/s41467-025-60216-3","article-title":"No evidence of immune exhaustion after repeated SARS-CoV-2 vaccination in vulnerable and healthy populations","volume":"16","author":"Benoit","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128511_bb0250","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1093\/infdis\/jiac419","article-title":"Effectiveness of mRNA booster vaccination against mild, moderate, and severe COVID-19 caused by the omicron variant in a large, population-based, Norwegian Cohort","volume":"226","author":"Laake","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128511_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2024-001074","article-title":"Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data","volume":"3","author":"Andersson","year":"2024","journal-title":"BMJ Med"},{"key":"10.1016\/j.vaccine.2026.128511_bb0260","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70081","article-title":"Effectiveness of the XBB.1.5 COVID-19 vaccines against SARS-CoV-2 hospitalisation among adults aged \u2265 65 years during the BA.2.86\/JN.1 predominant period, VEBIS hospital study, Europe, November 2023 to May 2024","volume":"19","author":"Antunes","year":"2025","journal-title":"Influenza Other Respir Viruses"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:00:02Z","timestamp":1792515602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26003191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":52,"alternative-id":["S0264410X26003191"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128511","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-lasting cross-reactive and polyfunctional SARS-CoV-2 T cell responses in seniors are maintained after repeated vaccination and infections","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128511"}}